The purpose of this study is to find the highest dose of an investigational drug called PRT062070 that can be given safely in patients with chronic lymphocytic leukemia (CLL), small cell lymphocytic leukemia (SLL), or B-cell non-Hodgkin lymphoma (NHL). There are standard therapies for these cancers, but sometimes the cancer stops responding to them or comes back after treatment is finished. Doctors are therefore seeking more effective therapies for these diseases.
PRT062070 is designed to inhibit cancer growth by blocking the activity of two proteins that cancer cells need to grow: spleen tyrosine kinase (Syk) and janus kinase (Jak). It is taken orally (by mouth).